XTX Topco Ltd Sells 2,990 Shares of argenx SE (NASDAQ:ARGX)

XTX Topco Ltd cut its stake in shares of argenx SE (NASDAQ:ARGX) by 59.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,040 shares of the company’s stock after selling 2,990 shares during the quarter. XTX Topco Ltd’s holdings in argenx were worth $1,255,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ARGX. Whipplewood Advisors LLC bought a new stake in shares of argenx during the 4th quarter valued at about $37,000. Global Retirement Partners LLC lifted its holdings in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares in the last quarter. FIL Ltd acquired a new position in shares of argenx during the fourth quarter valued at about $38,000. Jones Financial Companies Lllp boosted its stake in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after purchasing an additional 61 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in shares of argenx by 78.6% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock valued at $46,000 after buying an additional 33 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Oppenheimer upped their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Citigroup reissued an “outperform” rating on shares of argenx in a report on Friday, February 28th. Guggenheim boosted their target price on shares of argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a report on Monday, March 10th. Truist Financial reiterated a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average target price of $690.33.

argenx Price Performance

ARGX opened at $606.39 on Tuesday. The stock’s 50 day simple moving average is $606.57 and its 200 day simple moving average is $604.95. The firm has a market cap of $36.84 billion, a price-to-earnings ratio of -689.08 and a beta of 0.60. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, sell-side analysts anticipate that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.